glycoprotein-e2--hepatitis-c-virus and Cell-Transformation--Viral

glycoprotein-e2--hepatitis-c-virus has been researched along with Cell-Transformation--Viral* in 2 studies

Other Studies

2 other study(ies) available for glycoprotein-e2--hepatitis-c-virus and Cell-Transformation--Viral

ArticleYear
Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells.
    International journal of molecular medicine, 2015, Volume: 36, Issue:6

    Hepatitis C virus (HCV) E2 protein binds to CD81, which is a component of the B cell co-stimulatory complex. The E2-CD81 interaction leads to B cell proliferation, protein tyrosine phosphorylation and to the hypermutation of immunoglobulin genes. Epidemiological studies have reported a high prevalence of B cell non-Hodgkin lymphoma (NHL) in HCV-positive patients, suggesting a potential association between HCV and Epstein-Barr virus (EBV) in the genesis of B lymphocyte proliferative disorders. In the present study, in order to investigate the association between EBV and HCV in B cells, we created an in vitro EBV-induced B cell transformation model. CD81 was gradually overexpressed during transformation by EBV. B cells isolated from HCV-positive patients grew more rapidly and clumped together earlier than B cells isolated from healthy donors following EBV infection. Pre-stimulation of CD81 expressed by resting B cells with anti-CD81 monoclonal antibody (mAb) or HCV E2 accelerated the generation of lymphoblastoid cell lines (LCLs) by EBV infection. These cells proliferated prominently through the early expression of interleukin-10 and intracellular latent membrane protein (LMP)-l. By contrast, the overexpression of CD81 on EBV-transformed B cells by anti-CD81 mAb or HCV E2 protein induced apoptosis through reactive oxygen species (ROS)-mediated mitochondrial dysfunction. These results suggest that the engagement of CD81 expressed by B cells has differential effects on B cell fate (proliferation or apoptosis) according to EBV infection and the expression level of CD81.

    Topics: Adult; Antibodies; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Blotting, Western; Cell Proliferation; Cell Transformation, Viral; Cells, Cultured; Epstein-Barr Virus Infections; Female; Hepacivirus; Hepatitis C; Herpesvirus 4, Human; Host-Pathogen Interactions; Humans; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Middle Aged; Protein Binding; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Tetraspanin 28; Viral Envelope Proteins

2015
Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene.
    Molecular immunology, 2006, Volume: 43, Issue:12

    Envelope protein E2 of human hepatitis C virus (HCV) is an attractive component of a prototype HCV vaccine. Delivered by DNA immunogens, E2 evokes specific immune response of Th1-type, failing to induce either considerable antibody production, or T-helper cell proliferation. We aimed at modulating the immunogenic performance of E2 gene by changing the mode of protein expression in eukaryotic cells. Plasmids were constructed encoding full-length E2 and nonstructural protein 1 (p7) fused to either 13 or 38 C-terminal amino acids (aa) of HCV E1 that contain second hydrophobic segment of E1 stop-transfer signal, or a complete E1 stop-transfer signal with duplicated second hydrophobic segment. Injected into BALB/c mice, E2/p7 genes induced potent antibody and T-helper cell response targeted against hypervariable region 1, aa 472-586 of E2, and a novel epitope at aa 774-796 of p7. Profile of cytokines secreted by proliferating mouse splenocytes stimulated in vitro with E2- and p7-derived peptides, indicated mixed Th1/Th2 type of immune response. Thus, the full-length E2 and p7 genes supplied in one cassette were both immunogenic. E2/p7 containing a complete E1 stop-transfer signal with prolonged membrane spanning domain was superior to the shorter E2/p7 version in terms of both antibody and cellular immunogenicity. Optimal performance of HCV E2 could thus be achieved without the aid of external/heterologous signals by easing, through modification of the E2 signal sequence, the release of E2 from the rough ER while retaining full-length E2 and p7 sequences. This finding may help to improve the Th2 performance of HCV envelope genes as prototype vaccines.

    Topics: Amino Acid Sequence; Animals; Cell Line, Transformed; Cell Transformation, Viral; Chlorocebus aethiops; COS Cells; Escherichia coli; Genes, Viral; Genetic Variation; HeLa Cells; Hepacivirus; Humans; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Plasmids; Protein Sorting Signals; Viral Envelope Proteins; Viral Hepatitis Vaccines; Viral Proteins

2006